Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Thermo Fisher Scientific Inc.
TMO
$447.81 (+ $5.81 + 1.31%)
Last updated: Previous Close (2026-05-19)
About the Company
Thermo Fisher Scientific Inc. is a leading provider of life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services worldwide. The company serves pharmaceutical and biotech companies, hospitals, clinical diagnostic labs, universities, research institutions, government agencies, and sectors including environmental, industrial, research and development, quality, and process control. Its Life Sciences Solutions segment delivers reagents, instruments, and consumables for biological and medical research, drug and vaccine discovery and production, and disease diagnosis. The Analytical Instruments segment supplies tools, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and industrial applications, as well as clinical labs. Additional offerings include lab products, services through brands like Fisher Scientific and Unity Lab Services, and biopharma capabilities via Patheon and PPD. Thermo Fisher Scientific Inc., headquartered in Waltham, Massachusetts, supports customers across North America, Europe, and Asia-Pacific with innovative technologies and global distribution.
Price History
Latest News for TMO
Thermo Fisher Scientific acquires Clario for nearly $8.9bn
Clario will become part of Thermo Fisher’s laboratory products and biopharma services segment.
Thermo Fisher Scientific and SHL Medical Collaborate to Deliver Fully Integrated Drug-Device Solutions
RIDGEFIELD, N.J., March 25, 2026--Thermo Fisher Scientific Inc., the world leader in serving science, today announced a strategic collaboration with SHL Medical, a leading provider of advanced drug delivery systems, alongside an expansion of sterile fill-finish and autoinjector final assembly capacity at its Ridgefield, NJ site. Together, these investments establish a fully integrated U.S.-based offering spanning sterile manufacturing, device assembly and commercial packaging for drug-device com
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. On March 2, 2026, AIM ImmunoTech announced entering into an agreement with the PPD clinical research business of Thermo Fisher Scientific (TMO) to design a pivotal Phase 3 clinical trial for Ampligen. The study will […]
Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.
WALTHAM, Mass., March 24, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the completion of its acquisition of Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, for $8.875 billion in cash, plus potential additional earnout and other payments, largely dependent on performance. With the transaction complete, the Clario business will become part of Thermo Fisher’s Laboratory Products and Biopharma Services
Is Thermo Fisher Scientific (TMO) Pricing Look Attractive After Recent Share Price Weakness
Thermo Fisher Scientific might already be on your watchlist, but the real question is whether the current share price around US$474 reflects what you are actually getting for your money. Recent share price moves have been mixed, with the stock up 2.2% over the last week, while the 30 day return is a 7.2% decline and the year to date return sits at a 19.9% decline, contributing to a 1 year return of an 8.0% decline and a 3 year return of a 14.2% decline. These returns sit against an ongoing...
U.S. Exosomes Market to Skyrocket During 2026-2033, Reaching $716.8 Million - Analysis of Lucrative Business Opportunities and Key Players; Danaher, Thermo Fisher Scientific, Hologic, Fujifilm, Lonza and More
U.S. Exosomes Market U.S. Exosomes Market Dublin, March 20, 2026 (GLOBE NEWSWIRE) -- The "U.S. Exosomes Market Size, Share & Trends Analysis Report by Product & Service, Application, Workflow, End Use, and Segment Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering.The U.S. exosomes market size, valued at USD 115.6 million in 2025, is projected to surge to USD 716.8 million by 2033, marking a robust CAGR of 25.75% from 2026 to 2033. The market's expansion is largely driven